ISIS 2302 antisense inhibitor of ICAM-1 cell adhesion protein: Began Phase II trials in five diseases, with 20 to 40 patients in each study. Results should be a

Isis Pharmaceuticals Inc. (ISIP), Carlsbad, Calif.

Read the full 76 word article

How to gain access

Continue reading with a
two-week free trial.